Yaseswini Neelamraju

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/402276/publications.pdf

Version: 2024-02-01

1163117 1199594 21 414 8 12 citations g-index h-index papers 21 21 21 839 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The human RBPome: From genes and proteins to human disease. Journal of Proteomics, 2015, 127, 61-70.	2.4	106
2	Mutational landscape of RNA-binding proteins in human cancers. RNA Biology, 2018, 15, 115-129.	3.1	87
3	Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers. Scientific Reports, 2015, 5, 8765.	3.3	55
4	Splicing factor <i> <scp>ESRP</scp> 1 </i> controls <scp>ER</scp> â€positive breast cancer by altering metabolic pathways. EMBO Reports, 2019, 20, .	4.5	48
5	Frequent somatic <i>TET2</i> mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood, 2021, 138, 662-673.	1.4	30
6	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Modern Pathology, 2015, 28, 677-685.	5.5	28
7	Dissecting the expression relationships between RNA-binding proteins and their cognate targets in eukaryotic post-transcriptional regulatory networks. Scientific Reports, 2016, 6, 25711.	3.3	18
8	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine, 2022, 14, eabb7695.	12.4	13
9	Uncovering RNA binding proteins associated with age and gender during liver maturation. Scientific Reports, 2015, 5, 9512.	3.3	10
10	Database of RNA binding protein expression and disease dynamics (READ DB). Database: the Journal of Biological Databases and Curation, 2015, 2015, bav072.	3.0	9
11	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia, 2021, 35, 2688-2692.	7.2	7
12	Targeted detection and quantitation of histone modifications from 1,000 cells. PLoS ONE, 2020, 15, e0240829.	2.5	3
13	Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies. Blood, 2018, 132, 4050-4050.	1.4	O
14	Targeted detection and quantitation of histone modifications from 1,000 cells., 2020, 15, e0240829.		0
15	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
16	Targeted detection and quantitation of histone modifications from 1,000 cells., 2020, 15, e0240829.		0
17	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		О
18	Targeted detection and quantitation of histone modifications from 1,000 cells., 2020, 15, e0240829.		0

#	Article	IF	CITATIONS
19	Targeted detection and quantitation of histone modifications from 1,000 cells., 2020, 15, e0240829.		0
20	Targeted detection and quantitation of histone modifications from 1,000 cells., 2020, 15, e0240829.		0
21	Targeted detection and quantitation of histone modifications from 1,000 cells., 2020, 15, e0240829.		O